Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

News und Analysen

Wall Street Sees 48% or More Upside for These AI Stocks. Should You Buy Them?
Wall Street Sees 48% or More Upside for These AI Stocks. Should You Buy Them?

There's a lot of optimism on the long-term prospects of leading semiconductor makers. Big tech companies investing in artificial intelligence (AI) are requiring constant innovation in chip

Nvidia Stock: The Week of April 14-18 in Review
Nvidia Stock: The Week of April 14-18 in Review

Shares of Nvidia (NASDAQ: NVDA), the leading maker of artificial intelligence (AI) chips, dropped 8.5% last week, which was a four-day trading week due to the stock market being closed for the Good

Is AbbVie Stock a Buy?
Is AbbVie Stock a Buy?

It's been a stomach-churning past few months for investors in pharmaceutical giant AbbVie (NYSE: ABBV). A potential blockbuster drug that AbbVie spent roughly $9 billion to acquire the rights to

A Once-in-a-Decade Opportunity: 3 Magnificent Stocks Down Between 40% and 73% to Buy Right Now
A Once-in-a-Decade Opportunity: 3 Magnificent Stocks Down Between 40% and 73% to Buy Right Now

The S&P 500 has dropped 10% or more nine times since 2010, not including the current sell-off. However, the index has delivered an average return of 18% in the year following the start date of these

Is AMD Stock a Buy Before Its June Artificial Intelligence (AI) Event?
Is AMD Stock a Buy Before Its June Artificial Intelligence (AI) Event?

In today's video, I discuss Advanced Micro Devices (NASDAQ: AMD) and recent updates affecting the semiconductor market. To learn more, check out the short video, consider subscribing, and click the

3 Artificial Intelligence Stocks to Buy Before the Market Recovers
3 Artificial Intelligence Stocks to Buy Before the Market Recovers

The stock market has been volatile this year, and it's anyone's guess how things will continue to play out. If there's a recession, then the S&P 500 and stocks as a whole could be headed for even

Pfizer Abandons Its Leading Weight Loss Candidate. Should You Sell the Stock?
Pfizer Abandons Its Leading Weight Loss Candidate. Should You Sell the Stock?

Although it isn't the largest therapeutic area in the pharmaceutical industry, the market for weight loss therapies has caught fire in recent years. The leading medicines in this field include

Better Artificial Intelligence Stock: AT&T vs. SoundHound AI
Better Artificial Intelligence Stock: AT&T vs. SoundHound AI

Technology routinely affects nearly every part of the economy. In other words, companies that aren't traditional technology stocks can benefit from artificial intelligence (AI).

U.S

Don't Try to Time the Market: These 2 Stocks Are Buys Regardless of What Happens Next
Don't Try to Time the Market: These 2 Stocks Are Buys Regardless of What Happens Next

Equity markets have been seesawing for the past two weeks. Stocks fell hard after President Donald Trump announced his tariff plans, then bounced back big once he said he would pause expanded

Where Will Eli Lilly Be in 5 Years?
Where Will Eli Lilly Be in 5 Years?

What a difference five years can make. Just look at Eli Lilly (NYSE: LLY). In April 2020, the drugmaker stood in the shadows to some extent with companies including Johnson & Johnson, Pfizer, and

2 Dividend Stocks to Double Up on Right Now
2 Dividend Stocks to Double Up on Right Now

Dividend stocks are the best antidote for market volatility. There's nothing like seeing quarterly cash deposits in your account from industry-leading businesses. With the S&P 500 (SNPINDEX: ^GSPC)

Why Eli Lilly Stock Is Soaring Today, While Novo Nordisk and Viking Therapeutics Slide
Why Eli Lilly Stock Is Soaring Today, While Novo Nordisk and Viking Therapeutics Slide

It's Thursday morning, 11:50 a.m. ET -- and Eli Lilly (NYSE: LLY) stock is off to the races!

This morning, the Indianapolis-based pharmaceutical giant announced that its new GLP-1 weight loss pill

2 Stocks Down by 25% or More This Year to Buy and Hold
2 Stocks Down by 25% or More This Year to Buy and Hold

Equity markets have had a rough go of it this year due to President Trump's macroeconomic policies. Though it can be challenging to navigate this environment, one way to make the best of it is to

2 Dividend Stocks Defying the Tariff-Fueled Market Correction to Buy and Hold Forever
2 Dividend Stocks Defying the Tariff-Fueled Market Correction to Buy and Hold Forever

Equities are down this year because of Donald Trump's trade policies. The 47th U.S. president decided to impose steep tariffs on imported goods from most countries, although he has since

Great News for AMD Stock Investors
Great News for AMD Stock Investors

In this video, I go over recent updates regarding Advanced Micro Devices (NASDAQ: AMD). Watch the short video to learn more, consider subscribing, and click the special offer link below.

*Stock

EQS-News: Evotec SE unveils new strategy and provides 2025 guidance bolstered by strong Q4 2024 results
EQS-News: Evotec SE unveils new strategy and provides 2025 guidance bolstered by strong Q4 2024 results
EQS-News: Evotec SE unveils new strategy and provides 2025 guidance bolstered by strong Q4 2024 results
Aswath Damodaran on Investing in Uncertainty
Aswath Damodaran on Investing in Uncertainty

Aswath Damodaran teaches corporate finance and valuation at the Stern School of Business at New York University. In this podcast, Motley Fool Senior Analyst Matt Argersinger caught up with Damodaran

What Nvidia, AMD, and Intel Stock Investors Should Know About Recent Updates
What Nvidia, AMD, and Intel Stock Investors Should Know About Recent Updates

In today's video, I discuss Nvidia (NASDAQ: NVDA), Advanced Micro Devices (NASDAQ: AMD), Intel (NASDAQ: INTC), other technology stocks, and recent updates affecting the semiconductor market. To

EQS-News: Strong start to the year: Sartorius achieves significant profitable growth in the first quarter: https://www.sharewise.com/rails/active_storage/blobs/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBhQT09IiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--b12b7dfadf2c58d9e1a19e072122a740f7f20d88/Sartorius.svg?locale=us
EQS-News: Strong start to the year: Sartorius achieves significant profitable growth in the first quarter
EQS-News: Strong start to the year: Sartorius achieves significant profitable growth in the first quarter
Why Pfizer Stock Topped the Market on Tuesday
Why Pfizer Stock Topped the Market on Tuesday

On Tuesday, investors continued to snap up shares of big pharmaceutical company Pfizer (NYSE: PFE). Somewhat counterintuitively, this week's rise came after the company announced it was ending the

Down 71%, Should You Buy the Dip on Viking Therapeutics Stock?
Down 71%, Should You Buy the Dip on Viking Therapeutics Stock?

No one ever claimed investing in the biotech industry was a smooth ride, but for shareholders of Viking Therapeutics (NASDAQ: VKTX), the turbulence has been extremely challenging thus far. The stock

Is High-Yield Pfizer Stock Still a Buy After Scrapping Its Weight-Loss Pill?
Is High-Yield Pfizer Stock Still a Buy After Scrapping Its Weight-Loss Pill?

Pfizer (NYSE: PFE) recently reminded investors how risky the drug-development business can be. On April 14, the company told investors it would scrap development of danuglipron, its oral GLP-1

EQS-Adhoc: Carl Zeiss Meditec achieves significant earnings increase in Q2 2024/25
EQS-Adhoc: Carl Zeiss Meditec achieves significant earnings increase in Q2 2024/25
EQS-Adhoc: Carl Zeiss Meditec achieves significant earnings increase in Q2 2024/25
Why Eli Lilly, Novo Nordisk, and Viking Therapeutics Stocks All Popped Today
Why Eli Lilly, Novo Nordisk, and Viking Therapeutics Stocks All Popped Today

Bad news for Pfizer (NYSE: PFE) turned into good news for Eli Lilly (NYSE: LLY), Novo Nordisk (NYSE: NVO), and Viking Therapeutics (NASDAQ: VKTX) Monday morning, each of which is rising on Pfizer's

EQS-Adhoc: Drägerwerk AG & Co. KGaA: Preliminary figures Q1 2025: EBIT below prior year – forecast confirmed due to good order development
EQS-Adhoc: Drägerwerk AG & Co. KGaA: Preliminary figures Q1 2025: EBIT below prior year – forecast confirmed due to good order development
EQS-Adhoc: Drägerwerk AG & Co. KGaA: Preliminary figures Q1 2025: EBIT below prior year – forecast confirmed due to good order development